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Background: Understanding the molecular basis for the mixed profiles of progesterone receptor (PR) ligands will benefit
future drug design.
Results: Two differing mechanisms for the induction of mixed profiles by 11-steroids are described.
Conclusion: Subtle electrostatic and steric factors explain the differing PR activities of 11-steroids.
Significance: These observations will impact future drug-design strategies for PR and potentially other nuclear receptors.
We present here the x-ray structures of the progesterone
receptor (PR) in complex with twomixed profile PRmodulators
whose functional activity results from two differing molecular
mechanisms. The structure of Asoprisnil bound to the agonist
state of PR demonstrates the contribution of the ligand to
increasing stability of the agonist conformation of helix-12 via a
specific hydrogen-bond network includingGlu723. This interac-
tion is absent when the full antagonist, RU486, binds to PR.
Combined with a previously reported structure of Asoprisnil
bound to the antagonist state of the receptor, this structure
extends our understanding of the complex molecular interac-
tions underlying the mixed agonist/antagonist profile of the
compound. In addition, we present the structure of PR in its
agonist conformation bound to the mixed profile compound
Org3H whose reduced antagonistic activity and increased ago-
nistic activity compared with reference antagonists is due to an
induced fit around Trp755, resulting in a decreased steric clash
with Met909 but inducing a new internal clash with Val912 in
helix-12. This structure also explains the previously published
observation that 16 attachments to RU486 analogs induce
mixed profiles by altering the binding of 11 substituents.
Together these structures further our understanding of the
steric and electrostatic factors that contribute to the function of
steroid receptor modulators, providing valuable insight for
future compound design.
Modulation of the progesterone receptor (PR)2 is the mech-
anism of action for an array of medications and continues to be
a fertile area for research, with special focus on the develop-
ment of mixed profile compounds (1–3). Mixed profile modu-
lators of PR are characterized by decreased transcriptional
activity compared with full agonists and increased transcrip-
tional activity compared with full antagonists. Partial agonists,
often referred to as selective progesterone receptormodulators
(SPRMs), have the potential to treat a variety of women’s health
conditions (4–7) with improved safety and treatment profiles
compared with full agonists or antagonists.
Asoprisnil (Fig. 1), demonstrating a mixed agonist/antago-
nist profile depending on tissue type, was the first SPRM to
progress to late stage clinical development for the treatment of
uterine fibroids and endometriosis (8–14). However, themixed
profiles of SPRMs are often poorly reflected in classical in vitro
models (15). In our hands Asoprisnil is a full PR antagonist in
cell-based transactivation assays (PR agonist EC50 100nM, PR
antagonist EC50 0.14 nM with 96% efficacy compared with a
standard reference (16)) but can be characterized as a SPRM by
differences in in vivo models such as the McPhail test (mea-
suring endometrial proliferation in immature rabbits) com-
pared with the full antagonist RU486 (17). It has also been
shown clinically that Asoprisnil mediates unique endometrial
effects in healthy premenopausal women (17). Difficulties in
characterizing SPRMs in vitro have historically made their
identification and characterization problematic, but traditional
methods of steroid receptor drug discovery, designed to iden-
tify agonists and antagonists, are now being supplemented by
new design approaches and assay types, including peptide
recruitment and gene expression, better suited to characteriz-
ing mixed profile compounds (15).
The shared domain structure of steroid receptors, such as
PR, includes a variable N-terminal domain, a highly conserved
DNAbinding domain, and amoderately conserved ligand bind-
ing domain (LBD). The LBD combines a number of functions,
including hormone binding, receptor dimerization, and bind-
ing to other co-modulating proteins that play a role in the con-
trol of transcription. Specifically, gene activation requires the
The atomic coordinates and structure factors (codes 4A2J and 4APU) have been
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, NewBrunswick, NJ (http://www.rcsb.org/).
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2 Theabbreviationsusedare: PR,progesterone receptor; SPRM, selectiveproges-
terone receptormodulators; LBD, ligand binding domain; r.m.s.d., rootmean
square deviation; Org3H, 11-pyridinylphenyl steroids (17-cyclopro-
plycarbonyl-16-ethenyl-11-[4-(3-pyridinyl)phenyl]-estra-4,9-dien-3-one).
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recruitment of co-modulating proteins to a region of the sur-
face of the LBD formed by helices 3, 5, and 12. The position of
helix-12 can be influenced by the nature of the ligand bound to
the receptor, allowing ligands to influence the binding of co-
modulators and consequently gene activation. Our under-
standing of ligand binding to PR has been improved by a num-
ber of x-ray crystallography studies (18–23) that have also
furthered our understanding of the molecular mechanisms
underpinning antagonism and partial agonism (16, 17, 24–26).
In particular, it is well accepted that clashes between some
ligands andMet909 in helix-12 is a major contributing factor to
reduced agonistic activity.
One important recent publication describes the x-ray struc-
ture of Asoprisnil bound to the antagonist conformation of PR
in the presence of the co-repressors NCoR and SMRT (17). The
authors report the PR LBD in a conformation divergent from
the classical agonist state explaining the reduced agonistic
activity of the compound compared with full agonists. How-
ever, the structure gives only limited explanation for the com-
pound increased agonistic activity compared with other fully
antagonistic 11-steroids. The x-ray structure of Asoprisnil
bound to the antagonistic conformation of PR shows the ligand
polar oxime group to be in close contact to hydrophobic resi-
dues in the two described co-repressors (NCoR and SMRT)
(17). RU486 has a less polar dimethyl amine group in the posi-
tion equivalent to the Asoprisnil oxime, leading the authors to
hypothesize that RU486 might make stronger hydrophobic
contacts to co-repressors and, therefore, facilitate their recruit-
ment, thus explaining the differing biological activity of the two
compounds.
The same report demonstrates that Asoprisnil bound PR
does recruit co-activators such as SRC1. The ability for theAso-
prisnil-PR complex to recruit co-activators suggests the com-
plex is able to adopt an agonistic conformation in addition to
the antagonist conformation seen when in complex with co-re-
pressors. This is in line with the equilibrium model for partial
agonism (16, 27), which suggests thatmixed profile compounds
are able to partially stabilize their receptors in the agonist con-
formation compared with the complete stabilization elicited by
full agonists. This results in altered patterns of co-modulator
recruitment and modified biological outcomes. It also suggests
that although the agonistic conformation of PR bound to Aso-
prisnil may not be the lowest energy, it remains biologically
meaningful.
In an attempt to identify the basis for the ligands retained
agonistic activity comparedwith full antagonists such as RU486
(Fig. 1), we have used a previously described soaking technique
(16, 26) to determine the x-ray structure of the PR-Asoprisnil
complex in its agonist state. This has allowed us to identify an
interaction between the 11-benzaldoxime of Asoprisnil and
Glu723 that helps partially stabilize helix-12 in its agonist
conformation.
To establish if this mechanism is universal for 11-substi-
tuted steroids, we have also solved the x-ray structure of an
in-house SPRM from a class of 11-pyridinylphenyl steroids
(17-cycloproplycarbonyl-16-ethenyl-11-[4-(3-pyridinyl)-
phenyl]-estra-4,9-dien-3-one) that we refer to as Org3H (Fig.
1), with a previously disclosed mixed PR profile (PR agonist
EC50 0.66 nM with 47% efficacy, PR antagonist EC50 0.61 nM
with 38% (28)).
Elucidation of Org3H in complex with PR revealed a second
mechanism to explain its mixed profile compared with full
antagonists, with Org3H making a reduced clash with Met909
due to an induced fit around Trp755, which itself now clashes
with Val912 in helix-12. As a further consequence, the flipping
of Trp755 results in formation of an additional new subpocket.
Together these structures improve our molecular understand-
ing of the important steric and electrostatic factors contribut-
ing to the mixed profile seen for many PR modulators.
MATERIALS ANDMETHODS
Expression and Purification of PR-LBD—The PR LBD, com-
prising residues 678–933, was cloned in pET15b (Novagen).
Expression was performed in Escherichia coli BL21(DE3) star
(Invitrogen) in 2YT medium by overnight induction at 20 °C
in the presence of 10 M OrgA (Fig. 1). OrgA is a member of a
compound class described as glucocorticoid receptor antago-
nists (28) but is a relatively potent PR partial agonist whose
activity is described in a recent article (26). Bacteria were lysed
in buffer A (50 mM Tris, pH 7.8, 250 mMNaCl, 10% glycerol, 10
mM -mercaptoethanol) with 0.4 mM Pefablock (Roche
Applied Science) and 50 M OrgA and purified on nickel nitri-
lotriacetic acid. Fractions were eluted with buffer A with 100
mM imidazole. Elution fractionswere collected and treatedwith
2.5 wt/wt % thrombin (Kordia) overnight at 4 °C to cleave the
N-terminal His tag. Thrombin was removed by adding benz-
amidine-Sepharose (GEHealthcare), centrifuging for 10min at
5000  g, and harvesting the supernatant. To make the final
crystallization sample, the protein was dialyzed to buffer A to
which 1 mM EDTA, 1 mM dithiothreitol, and 10 MOrgA were
added and subsequently concentrated in a stirring cell to about
4 mg/ml as measured by its absorption at 280 nm. The sample
was stored at70 °C in aliquots of 50 l.
Crystallization—Crystals of the PR LBD in complex with
OrgA were grown at room temperature from 3.5-l drops
hanging over a mother liquor of 20–30% polyethylene glycol
3350, 0.1 M Hepes, pH 6.5, 100 mM Mg2SO4, and 10% (v/v)
glycerol. Drops consisted of 2 l of protein sample and 1 l of
mother liquor and 0.5 l of 40% 1,3-propanediol. Kite-shaped
crystals usually appeared after about 3 days.
Ligand Replacement—Crystals of the PR LBD in complex
with OrgA were collected and transferred to mother liquor to
which 0.25 mM concentrations of either Asoprisnil or Org3H
were added. 0.25mM is a significant excess of either compound.
The crystals were stored in a sitting drop at room temperature.
The solutions surrounding the crystals were replaced by fresh
solution 10 times over a period of 2 weeks. After this period, the
crystals were frozen and transferred for data collection.
Data Collection—Diffraction data were collected using a
Rigaku rotating-anode x-ray generator operating at 100 mA
and 50 kV. The dataset for the PR-Asoprisnil complex was col-
lected to 2.08 Å at 100 K and processed with mosflm/scala, and
the data for the PR-Org3H complex were collected to 1.9 Å at
100 K and processed with d*TREK/scala (29). Structures were
solved and refined using the CCP4i interface of the CCP4 soft-
ware suite (30). Data are summarized in Table 1. Although of
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similar resolution, the Asoprisnil dataset is somewhat weaker
than the Org3H dataset, and less water molecules were used
describe the electron density.
Modeling and Visualization—All figures have been gener-
ated using PyMOL (The PyMOL molecular graphics system,
Schrodinger, LLC). Ligand structures were optimized using the
semi-empirical quantum mechanical MOPAC module in
YASARA (31). YASARA was also used to calculate ligand vol-
umes, with all figures representing the volume of the solvent
accessible surface.
RESULTS ANDDISCUSSION
Size of 11GroupDoes Not Correlate to Antagonistic Activity—
The generally accepted mechanism for introducing PR antago-
nism into steroidal and non-steroidal compounds is via the
attachment of a bulky group at the steroids 11 position or an
equivalent position in non-steroidal compounds. This group
should clash with helix-12 and preclude it from adopting its
agonistic conformation. Impeding helix-12 from adopting its
agonistic position prevents the correct formation of the AF-2
surface and thus excludes the binding of co-activators. This
mechanism is supported by the x-ray structures of PR bound to
RU486 (16) and Asoprisnil (17) and structures of related recep-
tors such as the AR and glucocorticoid receptor (32–34). How-
ever, it has become clear to us that not all bulky groups are equal
in this respect and thatmore subtle factorsmust determine how
successfully each substituent is able to preclude helix-12. For
example, the side chain of the antagonist RU486has a volumeof
436 Å3, which although larger than the side chain of the SPRM
Asoprisnil at 385 Å3, is somewhat smaller than the side chain of
the second SPRM Org3H at 504 Å3.
This inconsistency suggests that steric contributions alone
do not guarantee the generation of full antagonists. It also sug-
gests that other factors must be involved in the inducement of
mixed profiles and that understanding these factorsmay help in
the future design of SPRMs. This promoted us to review the
available x-ray studies and generate new x-ray structures to
address this question.
Equilibrium Model for Steroid Receptor Function Suggests
Both Agonistic and Antagonistic Conformations Are Relevant
for Mixed Profile Compounds—It has been known since the
early 1990s that agonists and antagonists induce different con-
formational changes in PR (35, 36) with the demonstration that
the C-terminal is able to adopt two different positions corre-
sponding to the biological activity of the ligand (35, 37). Both of
these conformations are distinct from the conformation of the
unliganded. It was later shown that a third conformation could
be detected in the presence of 16-substituted analogs of
RU486 (38) known to be mixed-profile PR modulators. It has
since been postulated that full agonists promote interaction
with co-activators, and full antagonists change the conforma-
tion of the receptor to inhibit co-activator binding in favor of
co-repressor binding (10). In relation to this, mixed-profile
compounds induce an intermediate state of interaction
between receptor and co-modulators (38–40). The equilib-
riummodel for nuclear receptor agonism/antagonism suggests
thatmixed profile ligands partly stabilize the agonist conforma-
tion of their receptor (16, 27) and allow co-activators to bind
but with less efficacy than full agonists. The ability for the Aso-
prisnil-PR complex to recruit co-activators (17) suggests the
complex is able to adopt an agonistic conformation in addition
to the antagonist conformation seen when in complex with co-
repressors. It has also been shown for the steroid receptors that
the presence or absence of co-modulating proteins can alter the
specific conformation of structures resulting from x-ray crys-
tallography even after co-expression studies. For example, the
x-ray structure of genistein bound to the estrogen receptor-
has been reported in an agonist conformation in the presence of
co-activator but also in a conformation similar to the classic
antagonist conformation in the absence of co-activator (41, 42).
The binding of co-modulating proteins is itself a driving force in
the equilibrium and not just a consequence. The relative bal-
ance of co-activator and co-repressor expression within a given
target cell determines the relative agonist versus antagonist
activity of mixed-profile compounds (40). Although the previ-
ously reported structure of PR bound to Asoprisnil (from co-
expression studies) shows the receptor in an antagonist confor-
mation, it is in the presence of co-repressor. The ability of the
PR-Asoprisnil complex to recruit co-activators indicates the
agonist conformation of the receptor bound to Asoprisnil is
both viable and biologically meaningful. This conclusion led us
to utilize our previously described PR soaking method (16, 26)
to study Asoprisnil bound to a fixed agonistic conformation of
PR to determine whether this structure would give additional
insight into themolecular basis for Asoprisnil retained agonism
compared with RU486.
Asoprisnil Successfully Replaces OrgA during Soaking Ex-
periments—OrgA is a nonsteroidal compound (Fig. 1) with a
chemical structure distinct from 11-steroids whose PR activ-
ity and binding is well described in an earlier publication to
which we refer readers (26). PR forms homodimers endoge-
nously and also after crystallization. Fig. 2 shows the electron
density around Asoprisnil from the B monomer of a new x-ray
structure of PR in its agonistic conformation. The clarity of the
TABLE 1
Final crystallographic data and refinement statistics
Data in parentheses indicate the last resolution shell.
Structure PR-Asoprisnil PR-Org3H
Space group P21 P21
Unit cell (Å3) 58.61 64.70 69.99 57.66 64.37 70.47
-Angle (°) 95.7 96.3
Resolution (Å) 43.3-2.08 (2.19-2.08) 47.4-1.90 (2.00-1.90)
Completeness (%) 99.8 (100) 100 (99.9)
Rmerge 0.103 (0.496) 0.082 (0.729)
Mn2 (I/) 6.3 (2.0) 8.7 (2.1)
Multiplicity 3.1 (3.0) 4.1 (4.0)
R factor/Rfreeb 20.4/25.1 20.8/24.5
Atoms 4217 4289
Protein atoms 3967 4047
Ligand atoms 66 64
Water molecules 78 173
Other molecules e.g. sulfate 5 5
r.m.s.d. bonds, Å 0.011 0.078
r.m.s.d. angles (°) 1.2 1.05
B-factors (average Å2)
Main chain 36.0 40.5
Side chain 38.2 42.0
Water molecules 22.5 30.8
Ligand A chain 30.9 50.1 (OrgA)
Ligand B chain 29.3 37.5 (Org3H)
Wilson B-factor (Å2) 29.3 38.5
PDB identifier 4A2J 4APU
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electron density around the ligand allows us to conclude with a
high degree of confidence that OrgA has been completely
replaced by Asoprisnil during the soaking. The exchange is
complete for bothmonomers with the ligand in an almost iden-
tical binding mode. To aid in comparison with the previously
published RU486 structure in which the ligand soaks into only
the B monomer, we will describe only the equivalent monomer
from the new PR-Asoprisnil complex.
Helix-12 Is Well Ordered in Its Agonist Conformation—This
PR Asoprisnil complex is quite different from the public PR-
Asoprisnil structures (PDB access codes 2OVH and 2OVM)
and from the PR-RU486 structure (PDB access code 2W8Y).
The difference between the previously published PR-Asoprisnil
structures and this new structure is mainly located between
residues 881 and 924, as the classic antagonistic displacement
of helix-12 does not occur in this new structure (Fig. 3). Exclud-
ing the C-terminal residues after helix-11, the PR-agonist and
PR-antagonist structures bound to Asoprisnil show a root
mean square deviation (r.m.s.d.), calculated for their C atoms,
of 0.65 Å. Helix-12 is well ordered and in the agonist conforma-
tion compared with the poorly ordered helix-12 as observed
when bound to RU486. This is consistent with Asoprisnil
reduced antagonistic activity and its ability to recruit co-activa-
tors. There is, however, disorder in region 895–905, the con-
necting loop between helix-11 and helix-12 of both monomers
in the crystal. The loops of both monomers touch through a
symmetry contact and are also disordered in both PR-antago-
nist structures bound to Asoprisnil.
Soaking Asoprisnil into PR-Agonist Crystals Results in Same
Ligand Binding Mode as Co-expression—Despite the new PR-
Asoprisnil structure being in an agonistic conformation rather
than the antagonistic conformation of the previously reported
PR-Asoprisnil structures (17), the bindingmode of the ligand is
comparable. Asoprisnil orients itself almost identically within
the agonist and antagonist conformations of PR, making the
same contacts with the receptor. The 3-keto group makes the
classic interactions toGln725 andArg766 typical for oxosteroids,
with the 17 attachment occupying a hydrophobic pocket con-
sisting of Leu715, Leu718, Phe794, Leu797, Met801, and Tyr890
(Fig. 4). This pocket, referred to as the 17 pocket, has previ-
ously been described for a structure of PR bound to mometa-
sone furoate (21) and appears to provide additional room for
ligand expansion irrespective of agonism or antagonism.
No direct or indirect polar interaction exists between the
ligand and Asn719. The presence of a water-bridged interaction
between steroidal ligands and Asn719 has been described in
other PR-ligand complexes, including the binding of RU486
and norethindrone (26), but the 17-methoxy group of Aso-
prisnil sterically precludes the presence of a water molecule at
this position.
As can be seen in Fig. 5, the steroid scaffolds of Asoprisnil
fromboth the PR-agonist and PR-antagonist complexes are rel-
atively well overlaid with a small shift downward seen in Aso-
prisnil bound to the agonist conformation of PR. The 17 and
17 attachments of both compounds are also well overlaid. The
most significant difference between Asoprisnil bound to the
agonist conformation and the antagonist conformation of PR is
a 0.9 Å adjustment in the position of the oxime group. In the
agonistic complex the oxime and steroid core appear to sit
lower to reduce the clash with Met909 in helix-12. Because of
the displacement of helix-12 in the antagonistic complex, this
clash is not possible.FIGURE 1. The structures of progesterone (A), norethindrone (B), RU486
(C), Asoprisnil (D), Org3H (E), and OrgA (F) are shown.
FIGURE 2. 2Fo DFc OMIT electron density maps around the ligand and Met
909 for RU486 (A), Asoprisnil (B), and Org3H (C) are shown at 1. 0 .
Electron densities suggest a more stable conformation of Met909 in the Asoprisnil and Org3H structures compared with the RU486 complex.
DifferingMechanisms ExplainMixed Agonist/Antagonist Profile of 11-Steroids
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Met909 Is Better Ordered in Asoprisnil Complex Compared
with Equivalent RU486 Structure—In the past our group pub-
lished an x-ray structure of RU486 bound to the agonist con-
formation of PR (16), which clearly demonstrated disorder of
Met909 in helix-12 due to a clash with the ligand (Fig. 2A). This
clash resulted in the destabilization of helix-12, measured by
an increase in the b-factors of the helix compared with
helix-12 bound to previously described full agonists. This
provided a compelling model to explain the antagonistic
activity of RU486.
Met909 in the PR-agonist complex bound to Asoprisnil does
adopt a modified conformation compared with its position
bound to other full agonists, but the new rotamer is well
ordered, as can be seen when comparing the electron density of
each complex shown in Fig. 2. The increased order of helix-12
and particularlyMet909 in the Asoprisnil structure is consistent
with the increased agonistic activity of the ligand compared
with RU486.
As we investigated themolecular basis for this difference, we
considered the possibility that the reduced volume of Asopris-
nil oxime and its linear rather than branched nature, compared
with the dimethylamine of RU486, may reduce its clash with
Met909. However, comparison of the overlaid ligands did not
suggest a significant difference in their spatial arrangements
around the position of Met909 (Fig. 6), and therefore, other fac-
tors must be responsible that will be discussed in the following
section.
FIGURE 3. Panel A shows the secondary structure of the PR-Asoprisnil com-
plex generated by a soaking experiment described in this article. Helix-12
is colored red and is oriented in the classic agonist conformation. Panel
B shows the secondary structure of a previously described PR-Asoprisnil
complex generated (PDB code 2OVH) by co-expression with the ligand.
Helix-12 is colored red and is shifted from the agonist position to allow the
binding of a co-repressor peptide, colored blue. Protein-ligand complexes
were aligned using the Motif function in YASARA (31), and images were
generated using PyMOL.
FIGURE 4. Binding mode of Asoprisnil with hydrogen bonding from
Gln725 and Arg766 to the ligands 3-keto group, highlighted inmagenta.
Residues forming a hydrophobic pocket surrounding the 17 group are also
shown.
FIGURE 5. Asoprisnil from the PR-agonist conformation is shown (car-
bons are colored green) and overlaidwith Asoprisnil from the PR-antag-
onist conformation (carbons are colored magenta). Asoprisnil from the
PR-agonist conformation sits slightly lower in the pocket comparedwithAso-
prisnil from the PR-antagonist conformation.
FIGURE 6. Overlaid structures of PR-agonist structure bound to RU486
(carbonsarecoloredorange) comparedwithPR-agonist structurebound
to Asoprisnil (carbons are colored green). Hydrogen bonds between the
ligand keto groups to Gln725 and Arg766 are shown in magenta. Helix-12 is
colored redwith Met909 highlighted in both complexes (carbons are colored
red). The ligands overlay closely and appear to sterically impact onMet909 to a
similar degree.
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Asoprisnil Oxime Group Contributes to Stabilization of
Helix-12 in Its Agonistic Conformation—As previously de-
scribed (16, 43), Glu723 in helix-3 plays an important role in
stabilizing the agonist conformation of helix-12 by hydrogen
bonding to main chain amines in both Met908 and Met909 (Fig.
7A). In addition, Glu723 is also able tomake a hydrogen bond to
a water molecule in the bulk solvent. In the antagonistic con-
formation of PR bound to Asoprisnil, Glu723 points away from
the ligand to make polar contacts with the solvent and, due to
the displacement of helix-12, no longer makes stabilizing inter-
actions to Met908 and Met909.
In the agonistic conformation of PR-bound Asoprisnil,
Glu723, as expected, stabilizes the agonist position of helix-12
but, additionally, makes a hydrogen bond to the ligand oxime
group (Fig. 7B). In this new state Glu723 strengthens the hydro-
gen-bond network that stabilizes helix-12 in its agonistic posi-
tion. This interaction is not duplicated on binding of RU486,
which suggests the agonist conformation of PR bound to Aso-
prisnil is more stable than the agonist conformation of PR
bound to RU486. This relative increased stability of the agonist
conformation when bound to Asoprisnil explains the ability of
this complex to recruit co-activators and suggests that the
existence of the interaction with Glu723 pushes the receptor
equilibrium toward agonism compared with RU486.
Glu723 Is Equivalent to Asp351, Residue Crucial for Agonist/
Antagonist Balance in Estrogen Receptor —Glu723 in PR is
equivalent, based on sequence and structure alignments, to
Asp351 in the estrogen receptor , which plays a similar role in
stabilizing the agonist conformation of helix-12. The impor-
tance of this residue has been demonstrated by studying the
naturally occurringD351Ymutation and other syntheticmuta-
tions that result in loss of receptor agonistic activity, consistent
with the residues normal role in stabilizing the agonist confor-
mation of the receptor. Selectivemodulators of estrogen recep-
tor , referred to as SERMs and including raloxifene and
tamoxifen, contain an important basic amine function that is
almost ubiquitous among this drug class. The role of this nitro-
gen is to form a salt bridge to Asp351, requiring the amino acid
to adopt a new conformation and prevent it from undertaking
its usual function of stabilizing the agonistic conformation of
helix-12 (27, 41, 44–51, 53).
SERMs are, therefore, well characterized examples of ligands
whose mixed profiles can partly be attributed to disrupting the
stabilizing interaction of the conserved acidic residue at this
position. We believe that Asoprisnil is the first characterized
example of a ligand whose mixed profiles can be attributed to
strengthening this same stabilizing interaction.
Interaction with Glu723 Is Unlikely to Explain Partial Ago-
nismofOrg3H—The interaction betweenAsoprisnil andGlu723
is dependent on the presence of the 11-benzaldooxime group
and as such is unlikely to be a universal model for mixed profile
compounds. For example, Org3H is a SPRM from a class of
steroids incorporating 11-pyridinylphenyl groups and, there-
fore, lacks the hydrogen-bonddonating capacity of theAsopris-
nil oxime substituent. In an attempt to explain its partial ago-
nism, we selectedOrg3H as a candidate for characterization via
x-ray crystallography following the same soaking procedure as
we have described for Asoprisnil.
Org3H Is Bound toMonomer B but Not toMonomer A—As is
the case for our PR-Asoprisnil structure, the asymmetric unit
contains two copies of the PR-LBD. Visual inspection of the
electron density within the ligand binding pocket of the struc-
ture clearly shows thatmonomerB containsOrg3HbutOrgA is
still present in monomer A and has not been replaced during
the soaking. A similar observation was made when RU486
soaked into the B monomer of PR-norethindrone crystals
but failed to displace the original ligand from monomer A
(16). As Asoprisnil displaced OrgA in both monomers, we
can conclude that monomer A is accessible in the crystal but
must have lower affinity for Org3H or a slower rate of ligand
entry compared with monomer B. As hypothesized in the
RU486 study, this difference is likely to arise from conforma-
tional differences in the two crystallographically independ-
ent PR LBDs in the crystals. These differences are most
prominent around the loop 785–808, a region previously
hypothesized to be a route of entry for the ligand during the
soaking experiments (16).
FIGURE 7. Panel A illustrates the stabilizing interaction between Glu723 and helix-12 (colored red) by hydrogen bonding to the backbone of Met908 andMet909.
Panel B shows the binding mode of Asoprisnil bound to the agonist conformation of PR with ligand to receptor hydrogen bonds shown in magenta.
Interactions betweenGlu723 and helix-12 (shown in red) are also shown. Panel C shows a comparison between the effect of bindingAsoprisnil (green) to PR and
raloxifene (blue) to estrogen receptor . Binding of Asoprisnil to PR contributes the stabilizing interactions between Glu723 and the backbone of helix-12. On
the other hand, the binding of raloxifene to estrogen receptor  results in Asp351 losing its interactions with the backbone of helix-12 as it now prefers to
re-orientate and make a salt bridge to the ligands basic amine.
DifferingMechanisms ExplainMixed Agonist/Antagonist Profile of 11-Steroids
20338 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 24•JUNE 8, 2012
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on A
pril 17, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Steroidal Core of Org3H Binds Differently Than Other
Steroids—The binding of OrgA in monomer A is practically
identical to the previously described PR structures containing
OrgA and requires no further description (26). Org3H shares
the classical interaction with Gln725 and Arg766 via its 3-keto
group, with the A-ring in general binding in the conventional
manner described for RU486 and Asoprisnil. In the second
monomer Org3H shares the same scaffold as RU486 and Aso-
prisnil, but does not overlay as closely as these two ligands after
binding to the receptor (Fig. 8). Although the conformation of
the ligand is unchanged, the Org3H binding mode shows dis-
tinct unexpected differences, mostly around the D-ring, com-
paredwith the other steroids as it is shifted away from its typical
position toward the 17 pocket. Org3H does not have a 17
attachment, as seen for RU486 and Asoprisnil, but the reposi-
tioning of the D-ring is significant enough that the vinyl group
on position 16 ofOrg3H is oriented in a similar position to the
17 groups of RU486 and Asoprisnil, occupying a comparable
space within the receptor as shown in Fig. 8, A and B. This
overlay would not be possible if the steroid scaffold bound in
the classic position.
Induced Fit around Trp755 Relieves Clash with Met909—The
scaffold carbon atoms at C11 in RU486, Asoprisnil and Org3H
are all located at approximately the same position in their var-
ious co-crystals. The pendant attachments of RU486 and Aso-
prisnil, attached to C11, are also well overlaid and conserved.
The phenyl group attached at C11 of Org3H is, however, signif-
icantly divergent from the other reference compounds (Fig. 9).
The pyridinylphenyl fills a pocket resulting from a rearrange-
ment of Trp755.
Uponbinding ofOrg3H,Trp755 rotates 120° around the bond
between the residues C and C bond and 100° around the
bond between C and C (shown in Fig. 10, A and B). The new
orientation of Trp755 now packs against Leu726 in helix-3, pro-
viding space to accommodate the side chain of Org3H (shown
in Fig. 11, A and B). The capacity for Trp755 to adopt novel
positions has been described when the receptor binds to non-
steroidal compounds (24–26). In addition to these examples,
the same plasticity has been noted for the equivalent residue,
Trp741, in AR (34, 54–59).
The pyridinylphenyl side chain is able to occupy a channel
pointing toward His888 to which it makes a water-bridged
H-bond from the ligand pyridine nitrogen shown in Fig. 12. In
addition to His888 and the ligand, the conserved water is also
able to hydrogen-bond to the backbones of Tyr753 and Met756.
It has previously been observed that the Trp741 flip in AR
(equivalent to Trp755 in PR) makes available a channel and
potential interaction with His874 (equivalent to His888 in PR),
including the presence of the conserved water molecule. Com-
parison of all publicly available PR structures shows that this
channel has not previously been described for this receptor (Fig
13). It appears that the unusual orientation of Org3H steroidal
core is required to allow the 11 side chain to adopt this
position.
Effect of 16 Attachment Explains Structure Activity Rela-
tionship, Suggesting That This Substituent Induces Partial
Agonism—McDonnell and co-workers (38) have previously
reported the observation that 16 attachments on RU486 ana-
logs result in partial agonist activity rather than the full antag-
FIGURE 8. Panels A and B show the overlaid structures of Asoprisnil (car-
bons are in green), RU486 (carbons are in orange), and Org3H (carbons
are in cyan). The secondary structure of the PR-Asoprisnil structure is shown
as a schematic representation in green. The 17 side chains of Asoprisnil and
RU486 overlay relatively closelywith the 16 substituent of Org3Hdue to the
displacement of this compounds D-ring. In A, positions 16 and 17 of Org3H
and Asoprisnil are labeled. In B, position 16 of Org3H and Asoprisnil was
labeled.
FIGURE 9. Overlaid structure of Asoprisnil (carbons are in green), RU486
(carbons are in orange), and Org3H (carbons are in cyan). The secondary
structure of the PR-Asoprisnil structure is shown as a schematic representa-
tion in green. The 11 substituents of Asoprisnil and RU486 overlay closely,
but the 11 substituent of Org3H is clearly divergent.
FIGURE10.PanelA showsTrp755 fromtheAsoprisnil-boundcomplex (car-
bons are in green) and from the RU486-bound complex (carbons are in
orange) showing the normally observed rotamer for this residue. In con-
trast, Trp755 from the Org3H bound complex is shown (carbons are in cyan),
demonstrating its ligand inducedmovement.Panel B showsa similar scene to
panel A but with Org3H superimposed to show the clash it would make to
Trp755 if the amino acid was not shifted.
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onism that would otherwise be expected. They also suggest that
the basis for this effect is by altering the manner in which the
crucial 11 group of RU486 and its analogs interact with the
receptor but that crystallographic datawould be needed to con-
firm this. Our crystallography studies show that due to the 16
attachment onOrg3H, its steroidal scaffold binds in an atypical
fashion that consequently leads to the ligands 11 having a
reduced clash with Met909. Our PR-Org3H x-ray structure, the
first of PR bound to a 16-substituted PR modulator, supports
McDonnell’s hypothesis and suggests that the changing inter-
action between the receptor and the 11 groups they observed
is due to the utilization of the newly formed pocket behind
Trp755.
NewPosition of Trp755 Clashes withHelix-12—The divergent
position of the Org3H side chain results in a reduced clash with
Met909 compared with RU486, which is in agreement with the
increased agonistic activity of Org3H compared with RU486.
Met909 adopts a different conformation compared with the
rotamer reported when binding to the full agonist norethin-
drone (16, 21) but appears to be well tolerated (Fig. 2), even
making favorable hydrophobic contacts to the phenyl in the
ligands 11 attachment. This prompted us to hypothesize that
the remaining clash withMet909 may not be significant enough
on its own to explain the reduced agonistic activityOrg3Hcom-
pared with full agonists. We, therefore, continued examining
the structure to identify if any other factors were at play.
In its new position the Trp755 side chain is directed toward
Val912 in helix-12 and would clash with the position of this
residue in either the RU486 or Asoprisnil (ago conformation)
structures, as theywould bewithin 2Å. To relieve this potential
clash, Val912 is pushed away (1.5 Å average r.m.s.d. across all
non-hydrogen atoms but as much as 2.5 Å for some of the
side-chain atoms), and we observed a shift of helix-12 not pres-
ent in agonist structures or either the PR-agonist-Asoprisnil or
PR-agonist-RU486 structures (Fig 14).Wepreviously described
a PR structure bound to a full antagonist, OrgB, that also
induces a flipping of Trp755 (26) but does not result in the clash
with Val912 or the displacement of helix-12. So far, the indirect
destabilization of helix-12 independent ofMet909 appears to be
unique to this series of compounds and may explain why these
compounds are clearly mixed profile as measured in cell-based
in vitro assays, which typically characterize SPRMs as full
antagonists.
Stabilized Receptor Conformations Provide Valuable Ap-
proach for StudyingMixed ProfileModulators—Understanding
the molecular basis for mixed profile compounds is hampered
by the difficulty in determining relevant co-crystal structures.
Full agonists stabilize the receptor and, specifically, helix-12 in
a conformation suited to binding co-activating proteins, and
full antagonists stabilize the receptor in a conformation suited
to binding co-repressing proteins. The apparent reason for the
difficulty in co-crystallizing mixed profile compounds is that
they do not fully stabilize the receptor in either conformation,
FIGURE 11. Panel A shows a stick representation of Trp755 and a surface rep-
resentation of the binding pocket of the PR-agonist structure bound to Aso-
prisnil (ligand hidden for clarity). Panel B shows a stick representation of
Trp755 and a surface representation of the binding pocket of the PR-agonist
structure bound to Org3H (the ligand is hidden for clarity). The flipping of
Trp755 in the Org3H-bound complex expands the overall size of the pocket
and provides the opportunity for novel structure-based drug design.
FIGURE 12. Bindingmode of Org3Hwith the water (oxygen is shown as a
red sphere)-mediatedhydrogen-bond toHis888 is highlighted.Additional
interactions between the water molecule and Met756 are also shown.
FIGURE13.TheavailablePRLBDstructures in thePDBwerealignedusing
theMOTIF function inYASARAand the superimposed ligands extracted.
Amolecular surface encompassing the sum of the ligands was calculated by
PyMOL and shown is cyan. Org3Hwas added to the ligand alignment, and its
molecular surface was calculated and displayed as a red mesh. The portion of
the red mesh visible represents the additional space required for the toler-
ance of this ligand that has not previously been described for this receptor.
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adopting some degree of equilibrium between the two. This
equilibrium allows mixed profile compounds to bind unique
patterns of co-modulators compared with full agonists and
antagonists, resulting in their potentially interesting biological
effects. Unfortunately, as a result it also renders them poorly
suited to co-crystallization studies (60). Recently we have seen
the first publications describing methods to circumvent this
problem either by introducing stabilizing mutations into the
receptor (52, 56, 60) or by generating stable crystals of the
receptor using a receptor stabilizing ligand and then exchang-
ing this compound with other compounds of interest via soak-
ing (16). Both approaches have the potential to dramatically
increase our understanding of the biological mechanisms
underpinning partial agonism and provide novel insight for
drug optimization.
Implications of New PR Structures for Drug Design—All
ligands elicit their behaviors by a combination of their steric
and electrostatic character. The binding of PR agonists is the
result of a well described combination of steric complementa-
rity and specific electrostatic interactions, typically to Asn719,
Gln725, and Arg766. Our understanding of the additional inter-
actions that differentiate full antagonists and SPRMs from full
agonists have until now been limited to the steric properties of
bulky 11 substituents. The binding mode of Asoprisnil to the
agonist state of PR is the first description of how additional
electrostatic factors, specifically the interaction with Glu723,
can alter biological properties of SPRMs. Altering the nature of
that interaction by compound optimization has the potential to
fine-tune the characteristics of SPRMs with the aim to improve
their therapeutic response.
In addition to this new insight into the potential value of
modifying SPRMs via an electrostatic approach, the PR-Org3H
co-crystal also provides valuable new information regarding the
steric influences that will also benefit future drug design. In
particular we show how modifications away from the 11
group, such as the presence of 16 groups, can influence the
effect of the classic bulky substituent. This complex is also the
first indication that SPRMs can illicit their responses without
directly impeding helix-12 or clashing with Met909. A combi-
nation of the ligand-induced clash betweenTrp755 andVal912 in
helix-12 and the limited clash with Met909 suggest a unique
mechanism for the Org3H mixed profile. Overall we suggest
specific new directions for the design of SPRMs including the
exploration of the pocket behind Trp755, modification of inter-
actions with Glu723, and the generation of indirect clashes with
helix-12.
Conclusion—We present here two new PR structures bound
to partial agonists. The structures demonstrate that two dis-
tinct mechanisms explain themixed profiles of the two ligands,
indicating that both steric and electrostatic factors can contrib-
ute to this mixed PR activity. The additional information that
has been learned from the binding of Asoprisnil bound to the
agonist conformation of PR illustrates the value of studying
mixed profile compounds bound to both the agonist and antag-
onist conformations of their receptors as a useful tool for drug
design. This also supports the growing use of stabilized recep-
tor systems either by mutation or following soaking strategies
as shown here to study otherwise inaccessible receptor-ligand
complexes.
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